journal article·2026-02-05

The status of extracellular vesicles as drug carriers and therapeutics

Ameya P. Chaudhari, Omar M. Budayr, Emily E. Bonacquisti, Caden C. Kussatz, Mark S. Bannon, Karissa J. Law, Yusha Liu, Matthew L. Bolton, Patrick M. Glassman, Leaf Huang, Juliane Nguyen

Nature Reviews Bioengineering· Volume 4· Issue 4
Publisher page

Abstract

With their natural origin and biological compatibility, extracellular vesicles (EVs) are being recognized as next-generation vehicles for targeted drug delivery. Over the last two decades, the field of EV-based drug delivery has witnessed a substantial increase in published articles. While EVs hold tremendous potential as therapeutic carriers, their utility has been limited by issues such as heterogeneity, low yields, limited cargo loading efficiency, and rapid clearance by the mononuclear phagocyte system (MPS). In this review, we examine trends across research articles published between 2012 and 2024 (n = 38,177), focusing on key developments, persistent challenges, and evolving assumptions in the field. We provide an overview of the current EV landscape, discuss their organotropism, and discuss their application as carriers for nucleic acids and other therapeutic payloads. We highlight both their strengths and weaknesses compared to lipid nanoparticles and liposomes and assess the biodistribution of EVs as a function of labeling strategy and cell sources used. Finally, we outline translational considerations for EV-based therapeutics and propose additional reporting standards, complementing the MISEV 2023 guidelines.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Extracellular vesicles in disease · Nanoplatforms for cancer theranostics · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Jeppesen, D. K., Zhang, Q., Franklin, J. L. & Coffey, R. J. Extracellular vesicles and nanoparticles: emerging complexities. Trends Cell Biol. 33, 667–681 (2023).10.1016/j.tcb.2023.01.002 ↗
2. Kishore, R. & Khan, M. More than tiny sacks: stem cell exosomes as cell-free modality for cardiac repair. Circ. Res. 118, 330–343 (2016).10.1161/CIRCRESAHA.115.307654 ↗
3. Mulcahy, L. A., Pink, R. C. & Carter, D. R. F. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles 3, 24641 (2014).10.3402/jev.v3.24641 ↗
4. Dai, J. et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct. Target. Ther. 5, 145 (2020).10.1038/s41392-020-00261-0 ↗
5. Stahl, P. D. & Raposo, G. Extracellular vesicles: exosomes and microvesicles, integrators of homeostasis. Physiology 34, 169–177 (2019).10.1152/physiol.00045.2018 ↗
6. Ferguson, S. W. & Nguyen, J. Exosomes as therapeutics: the implications of molecular composition and exosomal heterogeneity. J. Control. Release 228, 179–190 (2016).10.1016/j.jconrel.2016.02.037 ↗
7. Liang, Y., Duan, L., Lu, J. & Xia, J. Engineering exosomes for targeted drug delivery. Theranostics 11, 3183–3195 (2021).10.7150/thno.52570 ↗
8. Bonacquisti, R. Engineering a genetically-encodable toolkit for tracking extracellular vesicle RNA cargo. PhD thesis, Univ. North Carolina Chapel Hill (2023).
9. Liang, X. et al. Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors. Nat. Commun. 16, 4028 (2025).10.1038/s41467-025-59377-y ↗
10. Wiklander, O. P. B. et al. Antibody-displaying extracellular vesicles for targeted cancer therapy. Nat. Biomed. Eng. 8, 1453–1468 (2024).10.1038/s41551-024-01214-6 ↗
11. Zhang, T., Zhang, L., Ma, X. & Song, W. The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics. Front. Cell Dev. Biol. 13, 1612589 (2025).10.3389/fcell.2025.1612589 ↗
12. Nguyen, J. & Fuhrmann, G. Extracellular vesicles — a versatile biomaterial. Adv. Healthc. Mater. 11, e2200192 (2022).10.1002/adhm.202200192 ↗
13. Delen, M. V., Derdelinckx, J., Wouters, K., Nelissen, I. & Cools, N. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J. Extracell. Vesicles 13, e12458 (2024).10.1002/jev2.12458 ↗
14. Fraiman, J. et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine 40, 5798–5805 (2022).10.1016/j.vaccine.2022.08.036 ↗
15. Murphy, D. E. et al. Natural or synthetic RNA Delivery: a stoichiometric comparison of extracellular vesicles and synthetic nanoparticles. Nano Lett. 21, 1888–1895 (2021).10.1021/acs.nanolett.1c00094 ↗
16. Kang, M., Jordan, V., Blenkiron, C. & Chamley, L. W. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J. Extracell. Vesicles 10, e12085 (2021).10.1002/jev2.12085 ↗
17. Anderson, J. D. et al. Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling. Stem Cell 34, 601–613 (2016).10.1002/stem.2298 ↗
18. Ferguson, S. W. et al. The microRNA regulatory landscape of MSC-derived exosomes: a systems view. Sci. Rep. 8, 1419 (2018).10.1038/s41598-018-19581-x ↗
19. Chansoria, P. et al. Instantly adhesive and ultra-elastic patches for dynamic organ and wound repair. Nat. Commun. 15, 4720 (2024).10.1038/s41467-024-48980-0 ↗
20. Hatzistergos, K. E., Blum, A., Ince, T., Grichnik, J. & Hare, J. M. What is the oncologic risk of stem cell treatment for heart disease? Circ. Res. 108, 1300–1303 (2011).10.1161/CIRCRESAHA.111.246611 ↗
21. Chiangjong, W., Netsirisawan, P., Hongeng, S. & Chutipongtanate, S. Red blood cell extracellular vesicle-based drug delivery: challenges and opportunities. Front. Med. 8, 761362 (2021).10.3389/fmed.2021.761362 ↗
22. Biagiotti, S. et al. Efficient and highly reproducible production of red blood cell-derived extracellular vesicle mimetics for the loading and delivery of RNA molecules. Sci. Rep. 14, 14610 (2024).10.1038/s41598-024-65623-y ↗
23. Usman, W. M. et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat. Commun. 9, 2359 (2018).10.1038/s41467-018-04791-8 ↗
24. Zhang, G. et al. Extracellular vesicles: natural liver-accumulating drug delivery vehicles for the treatment of liver diseases. J. Extracell. Vesicle 10, e12030 (2020).10.1002/jev2.12030 ↗
25. Wu, J., Piao, Y., Liu, Q. & Yang, X. Platelet-rich plasma-derived extracellular vesicles: a superior alternative in regenerative medicine? Cell Prolif. 54, e13123 (2021).10.1111/cpr.13123 ↗
26. Antich-Rosselló, M. et al. Platelet-derived extracellular vesicles for regenerative medicine. Int. J. Mol. Sci. 22, 8580 (2021).10.3390/ijms22168580 ↗
27. Wang, Z., Wang, Q., Qin, F. & Chen, J. Exosomes: a promising avenue for cancer diagnosis beyond treatment. Front. Cell Dev. Biol. 12, 1344705 (2024).10.3389/fcell.2024.1344705 ↗
28. Wang, X. et al. Exosomes and cancer — diagnostic and prognostic biomarkers and therapeutic vehicle. Oncogenesis 11, 54 (2022).10.1038/s41389-022-00431-5 ↗
29. McNamara, R. P. et al. Exosome-encased nucleic acid scaffold chemotherapeutic agents for superior anti-tumor and anti-angiogenesis activity. ACS Bio Med Chem Au 2, 140–149 (2022).10.1021/acsbiomedchemau.1c00030 ↗
30. Nguyen, V. D., Kim, H. Y., Choi, Y. H., Park, J.-O. & Choi, E. Tumor-derived extracellular vesicles for the active targeting and effective treatment of colorectal tumors in vivo. Drug Deliv. 29, 2621–2631 (2022).10.1080/10717544.2022.2105444 ↗
31. Feng, L., Guo, L., Tanaka, Y. & Su, L. Tumor-derived small extracellular vesicles involved in breast cancer progression and drug resistance. Int. J. Mol. Sci. 23, 15236 (2022).10.3390/ijms232315236 ↗
32. Guo, X., Sui, R. & Piao, H. Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma. J. Nanobiotechnol. 20, 383 (2022).10.1186/s12951-022-01584-6 ↗
33. Haney, M. J. et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J. Control. Release 207, 18–30 (2015).10.1016/j.jconrel.2015.03.033 ↗
34. Yuan, D. et al. Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials 142, 1–12 (2017).10.1016/j.biomaterials.2017.07.011 ↗
35. Aiello, S. et al. Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. Sci. Rep. 7, 11518 (2017).10.1038/s41598-017-08617-3 ↗
36. Fernández-Messina, L., Gutiérrez-Vázquez, C., Rivas-García, E., Sánchez-Madrid, F. & de la Fuente, H. Immunomodulatory role of microRNAs transferred by extracellular vesicles. Biol. Cell 107, 61–77 (2015).10.1111/boc.201400081 ↗
37. Kim, M. S. et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine 14, 195–204 (2018).10.1016/j.nano.2017.09.011 ↗
38. Williams, A. et al. Targeting of extracellular vesicle-based therapeutics to the brain. Cell 14, 548 (2025).10.3390/cells14070548 ↗
39. Cheng, L., Wang, Y. & Huang, L. Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node. Mol. Ther. 25, 1665–1675 (2017).10.1016/j.ymthe.2017.02.007 ↗
40. Tan, E., Chin, C. S. H., Lim, Z. F. S. & Ng, S. K. HEK293 cell line as a platform to produce recombinant proteins and viral vectors. Front. Bioeng. Biotechnol. 9, 796991 (2021).10.3389/fbioe.2021.796991 ↗
41. Ohno, S.-I. et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21, 185–191 (2013).10.1038/mt.2012.180 ↗
42. Wang, C. et al. Engineering a HEK-293T exosome-based delivery platform for efficient tumor-targeting chemotherapy/internal irradiation combination therapy. J. Nanobiotechnol. 20, 247 (2022).10.1186/s12951-022-01462-1 ↗
43. Sung, B. H. et al. A live cell reporter of exosome secretion and uptake reveals pathfinding behavior of migrating cells. Nat. Commun. 11, 2092 (2020).10.1038/s41467-020-15747-2 ↗
44. Tieu, A. et al. Biodistribution of mesenchymal stromal cell-derived extracellular vesicles administered during acute lung injury. Stem Cell Res. Ther. 14, 250 (2023).10.1186/s13287-023-03472-8 ↗
45. Kronstadt, S. M., Heyningen, L. H. V., Aranda, A. & Jay, S. M. Assessment of anti-inflammatory bioactivity of extracellular vesicles is susceptible to error via media component contamination. Cytotherapy 25, 387–396 (2023).10.1016/j.jcyt.2022.12.002 ↗
46. Zhu, X. et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J. Extracell. Vesicles 6, 1324730 (2017).10.1080/20013078.2017.1324730 ↗
47. Saleh, A. F. et al. Extracellular vesicles induce minimal hepatotoxicity and immunogenicity. Nanoscale 11, 6990–7001 (2019).10.1039/C8NR08720B ↗
48. Ferguson, S., Kim, S., Lee, C., Deci, M. & Nguyen, J. The phenotypic effects of exosomes secreted from distinct cellular sources: a comparative study based on miRNA composition. AAPS J. 20, 67 (2018).10.1208/s12248-018-0227-4 ↗
49. Hagey, D. W. et al. The cellular response to extracellular vesicles is dependent on their cell source and dose. Sci. Adv. 9, eadh1168 (2023).10.1126/sciadv.adh1168 ↗
50. Escudier, B. et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J. Transl. Med. 3, 10 (2005).10.1186/1479-5876-3-10 ↗
51. Maxson, S., Lopez, E. A., Yoo, D., Danilkovitch-Miagkova, A. & LeRoux, M. A. Concise Review: role of mesenchymal stem cells in wound repair. Stem Cell Transl. Med. 1, 142–149 (2012).10.5966/sctm.2011-0018 ↗
52. Wang, J. et al. Boosting the biogenesis and secretion of mesenchymal stem cell-derived exosomes. Cell 9, 660 (2020).10.3390/cells9030660 ↗
53. Wang, J. et al. MiR-101a loaded extracellular nanovesicles as bioactive carriers for cardiac repair. Nanomedicine 27, 102201 (2020).10.1016/j.nano.2020.102201 ↗
54. Jasiewicz, N. E. et al. In situ-crosslinked Zippersomes enhance cardiac repair by increasing accumulation and retention. Bioeng. Transl. Med. 9, e10697 (2024).10.1002/btm2.10697 ↗
55. Zhang, K. & Cheng, K. Stem cell-derived exosome versus stem cell therapy. Nat. Rev. Bioeng. 1, 608–609 (2023).10.1038/s44222-023-00064-2 ↗
56. Popowski, K. D. et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter 5, 2960–2974 (2022).10.1016/j.matt.2022.06.012 ↗
57. Carney, R. P. et al. Harnessing extracellular vesicle heterogeneity for diagnostic and therapeutic applications. Nat. Nanotechnol. 20, 14–25 (2024).10.1038/s41565-024-01774-3 ↗
58. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04493242 (2024).
59. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04491240 (2020).
60. Margiana, R. et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res. Ther. 13, 366 (2022).10.1186/s13287-022-03054-0 ↗
61. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006).10.1016/j.cell.2006.07.024 ↗
62. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).10.1016/j.cell.2007.11.019 ↗
63. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05523011 (2024).
64. Chandran, N. S. et al. A phase 1, open-label study to determine safety and tolerability of the topical application of mesenchymal stem/stromal cell (MSC) exosome ointment to treat psoriasis in healthy volunteers. Cytotherapy 27, 633–641 (2025).10.1016/j.jcyt.2025.01.007 ↗
65. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03608631 (2025).
66. Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498–503 (2017).10.1038/nature22341 ↗
67. Surana, R. et al. Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRASG12D siRNA in patients with metastatic pancreatic cancer harboring a KRASG12D mutation. J. Clin. Oncol. 40, TPS633 (2022).10.1200/JCO.2022.40.4_suppl.TPS633 ↗
68. Mendt, M. et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3, e99263 (2018).10.1172/jci.insight.99263 ↗
69. Kalluri, V. S. et al. Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Nat. Commun. 16, 8696 (2025).10.1038/s41467-025-63718-2 ↗
70. Yang, Y. et al. Acquisition of new tumor cell properties by MSC-derived exosomes. Int. J. Oncol. 47, 244–252 (2015).10.3892/ijo.2015.3001 ↗
71. Roccaro, A. M. et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123, 1542–1555 (2013).10.1172/JCI66517 ↗
72. Zhu, W. et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 315, 28–37 (2012).10.1016/j.canlet.2011.10.002 ↗
73. Wang, J. et al. Mesenchymal stem cell-derived extracellular vesicles alter disease outcomes via endorsement of macrophage polarization. Stem Cell Res. Ther. 11, 424 (2020).10.1186/s13287-020-01937-8 ↗
74. Zhao, R., Chen, X., Song, H., Bie, Q. & Zhang, B. Dual role of MSC-derived exosomes in tumor development. Stem Cell Int. 2020, 8844730 (2020).
75. Adlerz, K., Patel, D., Rowley, J., Ng, K. & Ahsan, T. Strategies for scalable manufacturing and translation of MSC-derived extracellular vesicles. Stem Cell Res. 48, 101978 (2020).10.1016/j.scr.2020.101978 ↗
76. Xia, Y., Zhang, J., Liu, G. & Wolfram, J. Immunogenicity of extracellular vesicles. Adv. Mater. 36, 2403199 (2024).10.1002/adma.202403199 ↗
77. Zeng, F. et al. Graft-derived extracellular vesicles transported across subcapsular sinus macrophages elicit B cell alloimmunity after transplantation. Sci. Transl. Med. 13, eabb0122 (2021).10.1126/scitranslmed.abb0122 ↗
78. Labusek, N. et al. Extracellular vesicles from immortalized mesenchymal stromal cells protect against neonatal hypoxic-ischemic brain injury. Inflamm. Regen. 43, 24 (2023).10.1186/s41232-023-00274-6 ↗
79. Shitova, M., Alpeeva, E. & Vorotelyak, E. Review of hTERT-immortalized cells: how to assess immortality and confirm identity. Int. J. Mol. Sci. 25, 13054 (2024).10.3390/ijms252313054 ↗
80. Lin, Y. C. et al. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat. Commun. 5, 4767 (2014).10.1038/ncomms5767 ↗
81. Lilyestrom, W., Klein, M. G., Zhang, R., Joachimiak, A. & Chen, X. S. Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev. 20, 2373–2382 (2006).10.1101/gad.1456306 ↗
82. US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05216562 (2022).
83. Gonzalez-King, H. et al. Hypoxia inducible factor-1α potentiates jagged 1-mediated angiogenesis by mesenchymal stem cell-derived exosomes. Stem Cell 35, 1747–1759 (2017).10.1002/stem.2618 ↗
84. Arslan, F. et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 10, 301–312 (2013).10.1016/j.scr.2013.01.002 ↗
85. Jasiewicz, N., Drabenstott, C. & Nguyen, J. Harnessing the full potential of extracellular vesicles as drug carriers. Curr. Opin. Colloid Interface Sci. 51, 101412 (2021).10.1016/j.cocis.2020.101412 ↗
86. Bader, J., Brigger, F. & Leroux, J.-C. Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids. Adv. Drug Deliv. Rev. 215, 115461 (2024).10.1016/j.addr.2024.115461 ↗
87. Zeng, H. et al. Current strategies for exosome cargo loading and targeting delivery. Cells 12, 1416 (2023).10.3390/cells12101416 ↗
88. Luan, X. et al. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017).10.1038/aps.2017.12 ↗
89. Liu, M. et al. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat. Nanotechnol. 19, 565–575 (2024).10.1038/s41565-023-01580-3 ↗
90. Kim, M. S. et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12, 655–664 (2016).10.1016/j.nano.2015.10.012 ↗
91. Le Saux, S. et al. Post-production modifications of murine mesenchymal stem cell (mMSC) derived extracellular vesicles (EVs) and impact on their cellular interaction. Biomaterials 231, 119675 (2020).10.1016/j.biomaterials.2019.119675 ↗
92. Nizamudeen, Z. A. et al. Low-power sonication can alter extracellular vesicle size and properties. Cells 10, 2413 (2021).10.3390/cells10092413 ↗
93. Chen, W. Electroconformational denaturation of membrane proteins. Ann. N. Y. Acad. Sci. 1066, 92–105 (2005).10.1196/annals.1363.028 ↗
94. Bangham, A. D. & Horne, R. W. Action of saponin on biological cell membranes. Nature 196, 952–953 (1962).10.1038/196952a0 ↗
95. Patel, G. K. et al. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci. Rep. 9, 5335 (2019).10.1038/s41598-019-41800-2 ↗
96. Linares, R., Tan, S., Gounou, C., Arraud, N. & Brisson, A. R. High-speed centrifugation induces aggregation of extracellular vesicles. J. Extracell. Vesicle 4, 29509 (2015).10.3402/jev.v4.29509 ↗
97. Li, Z. et al. In vitro and in vivo RNA inhibition by CD9-HuR functionalized exosomes encapsulated with miRNA or CRISPR/dCas9. Nano Lett. 19, 19–28 (2019).10.1021/acs.nanolett.8b02689 ↗
98. Gee, P. et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat. Commun. 11, 1334 (2020).10.1038/s41467-020-14957-y ↗
99. Chitti, S. V. et al. Vesiclepedia 2024: an extracellular vesicles and extracellular particles repository. Nucleic Acids Res. 52, D1694–D1698 (2023).10.1093/nar/gkad1007 ↗
100. Keerthikumar, S. et al. ExoCarta: a web-based compendium of exosomal cargo. J. Mol. Biol. 428, 688–692 (2016).10.1016/j.jmb.2015.09.019 ↗